Among prognostic molecular assays, the Oncotype DX 21-gene assay [7–9] and the MammaPrint 70-gene assay [10, 11] were also validated to predict chemotherapy benefit for patients with hormone receptor-positive early breast cancer. This evidence concerns the gene NR4A1 and breast cancer.